Vesicular systems in ocular drug delivery: an overview
- PMID: 14698571
- DOI: 10.1016/j.ijpharm.2003.09.016
Vesicular systems in ocular drug delivery: an overview
Abstract
The main aim of pharmacotherapeutics is the attainment of effective drug concentration at the intended site of action for a sufficient period of time to elicit a response. Poor bioavailability of drugs from ocular dosage form is mainly due to the tear production, non-productive absorption, transient residence time, and impermeability of corneal epithelium. Though the topical and localized application are still an acceptable and preferred way to achieve therapeutic level of drugs used to treat ocular disorders but the primitive ophthalmic solution, suspension, and ointment dosage form are no longer sufficient to combat various ocular diseases. This article reviews the constraints with conventional ocular therapy and explores various novel approaches, in general, to improve ocular bioavailability of the drugs, advantages of vesicular approach over these and the future challenges to render the vesicular system more effective.
Similar articles
-
Ocular preparations: the formulation approach.Drug Dev Ind Pharm. 2002 May;28(5):473-93. doi: 10.1081/ddc-120003445. Drug Dev Ind Pharm. 2002. PMID: 12098838 Review.
-
Review of ocular drug delivery.Curr Drug Deliv. 2006 Apr;3(2):207-17. doi: 10.2174/156720106776359186. Curr Drug Deliv. 2006. PMID: 16611007 Review.
-
Recent advances in ocular drug delivery.Drug Dev Ind Pharm. 2013 Nov;39(11):1599-617. doi: 10.3109/03639045.2012.736515. Epub 2012 Nov 16. Drug Dev Ind Pharm. 2013. PMID: 23153114 Review.
-
Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery.Adv Drug Deliv Rev. 2008 Dec 14;60(15):1663-73. doi: 10.1016/j.addr.2008.09.002. Epub 2008 Sep 20. Adv Drug Deliv Rev. 2008. PMID: 18845195 Review.
-
Colloidal carriers for ophthalmic drug delivery.Curr Drug Targets. 2005 May;6(3):363-71. doi: 10.2174/1389450053765914. Curr Drug Targets. 2005. PMID: 15857294 Review.
Cited by
-
Formulation and evaluation of an in situ gel-forming ophthalmic formulation of moxifloxacin hydrochloride.Int J Pharm Investig. 2012 Apr;2(2):78-82. doi: 10.4103/2230-973X.100042. Int J Pharm Investig. 2012. PMID: 23119236 Free PMC article.
-
Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment.Int J Nanomedicine. 2020 Aug 6;15:5745-5765. doi: 10.2147/IJN.S254792. eCollection 2020. Int J Nanomedicine. 2020. PMID: 32821099 Free PMC article. Review.
-
Progress in Nanotechnology for Treating Ocular Surface Chemical Injuries: Reflecting on Advances in Ophthalmology.Adv Sci (Weinh). 2025 Feb;12(6):e2407340. doi: 10.1002/advs.202407340. Epub 2025 Jan 4. Adv Sci (Weinh). 2025. PMID: 39755928 Free PMC article. Review.
-
Recent progress of nanomedicine in managing dry eye disease.Adv Ophthalmol Pract Res. 2024 Jan 29;4(1):23-31. doi: 10.1016/j.aopr.2024.01.008. eCollection 2024 Feb-Mar. Adv Ophthalmol Pract Res. 2024. PMID: 38356795 Free PMC article. Review.
-
Physicochemical and Stability Evaluation of Topical Niosomal Encapsulating Fosinopril/γ-Cyclodextrin Complex for Ocular Delivery.Pharmaceutics. 2022 May 27;14(6):1147. doi: 10.3390/pharmaceutics14061147. Pharmaceutics. 2022. PMID: 35745720 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
